Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Market Closed 11-22 16:00:00 EST

244.89

-1.91

-0.77%

盘后244.40

-0.49-0.20%

19:59 EST

High248.90	Low243.35	Vol526.15K
Open248.90	D1 Closing246.80	Amplitude2.25%
Mkt Cap31.59B	Tradable Cap31.45B	Total Shares128.98M
T/O129.12M	T/O Rate0.41%	Tradable Shares128.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":244.89,"timestamp":1732309200000,"preClose":246.8,"halted":0,"volume":526150,"hourTrading":{"tag":"盘后","latestPrice":244.4,"preClose":244.89,"latestTime":"19:59 EST","volume":77629,"amount":19008893.93,"timestamp":1732323598085},"delay":0,"floatShares":128436320,"shares":128980917,"eps":-2.620895,"marketStatus":"Market Closed","change":-1.91,"latestTime":"11-22 16:00:00 EST","open":248.9,"high":248.9,"low":243.35,"amount":129123034.4805,"amplitude":0.022488,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.620895,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":246.8,"preHourTrading":{"tag":"盘前","latestPrice":249.09,"preClose":246.8,"latestTime":"09:08 EST","volume":7176,"amount":1772479.8936,"timestamp":1732284525217},"postHourTrading":{"tag":"盘后","latestPrice":244.4,"preClose":244.89,"latestTime":"19:59 EST","volume":77629,"amount":19008893.93,"timestamp":1732323598085},"volumeRatio":0.4459026352050289,"impliedVol":0.4379,"impliedVolPercentile":0.5873},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2485241868","title":"US FDA approves BridgeBio's drug for rare heart condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2485241868","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485241868?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:21","pubTimestamp":1732321267,"startTime":"0","endTime":"0","summary":"Nov 22  - The U.S. Food and Drug Administration has approved BridgeBio's    drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's    blockbuster Vyndaqel.   The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy , in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00B19Z3581.USD","LU0868494617.USD","SG9999001176.SGD","LU0306807586.USD","LU0234572021.USD","SG9999002224.SGD","LU1894683264.USD","SG9999003800.SGD","LU0985481810.HKD","LU0321505439.SGD","LU0321505868.SGD","LU0456855351.SGD","BK4592","BK4534","BBIO","LU1057294990.SGD","PFE","BK4505","BK4585","LU1066051498.USD","IE0002270589.USD","LU0058720904.USD","SG9999002232.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1894683348.USD","BK4588","LU0225284248.USD","BK4007","BK4550","IE00BBT3K403.USD","LU0122379950.USD","SGXZ57979304.SGD","LU1066053197.SGD","LU1023059063.AUD","ALNY","LU0170899867.USD","BK4568","BK4599","LU0225771236.USD","BK4139","BK4548","LU0306806265.USD","SG9999011175.SGD","IE00BLSP4239.USD","SG9999013999.USD","LU0289739699.SGD","BK4581"],"gpt_icon":1},{"id":"2484687994","title":"MEDIA-Jefferies taps former Alnylam CEO John Maraganore as senior adviser - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2484687994","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484687994?lang=en_us&edition=fundamental","pubTime":"2024-11-19 16:51","pubTimestamp":1732006267,"startTime":"0","endTime":"0","summary":"MEDIA-Jefferies taps former Alnylam CEO John Maraganore as senior adviser - Bloomberg News -- Source link: https://tinyurl.com/2bf23wjq-- Note: Reuters has not verified this story and does not vouch for its accuracy ((Bengaluru newsroom, globalnewsmonitoring@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4N3MQ0ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","ALNY","JEF","BK4127","BK4548"],"gpt_icon":0},{"id":"2484601565","title":"Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484601565","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484601565?lang=en_us&edition=fundamental","pubTime":"2024-11-19 01:59","pubTimestamp":1731952740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 12:59 ET (17:59 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2484234674","title":"ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484234674","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484234674?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:26","pubTimestamp":1731939960,"startTime":"0","endTime":"0","summary":"The ongoing phase I study evaluates the safety, tolerability, pharmacokinetic  and pharmacodynamic effects of nucresiran in 48 healthy adult subjects, who have been randomized in a ratio of 3:1 to receive either a single ascending dose of nucresiran or placebo. The study's primary endpoint is safety and secondary endpoints include the change from baseline in serum TTR over time, as well as characterization of plasma and urine PK of nucresiran.ALNY’s Amyloidosis Drug Shows Sustained 6-Month Efficacy. Per the data from an interim analysis of the phase I ATTR amyloidosis study, it was observed that a single 300 mg or higher dose of nucresiran quickly reduced serum TTR levels with low inter-patient variability, by more than 90% within 15 days, sustained through at least six months. At these dosage strengths, the reduction of mean TTR levels peaked at more than 96% by Day 29. Furthermore, serum TTR levelsremained significantly reduced, with a mean decrease of more than 70% at the one-year m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alny-reports-sustained-6-month-142600613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","IE00BBT3K403.USD","PK","SGXZ57979304.SGD","SG9999013999.USD","LU0306807586.USD","LU0889565916.HKD","LU0321505439.SGD","IE00B19Z3581.USD","LU0234572021.USD","LU1057294990.SGD","LU0058720904.USD","BK4566","GILD","LU1066053197.SGD","BK4533","LU1585245621.USD","LU1023059063.AUD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU1839511570.USD","SG9999011175.SGD","SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","BK4532","SG9999003800.SGD","LU0321505868.SGD","SG9999002232.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0456855351.SGD","LU1066051498.USD","BK4568","ALNY","SG9999001176.SGD","BK4583","BK4534","BK4578","IE00BSNM7G36.USD","BK4218","ALLO","LU1430594728.SGD","BK4592","BK4007","PFE","LU0320765992.SGD","SG9999002224.SGD","LU0225771236.USD","BK4139"],"gpt_icon":1},{"id":"2484262126","title":"TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484262126","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484262126?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:36","pubTimestamp":1731933389,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $37...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","ALNY"],"gpt_icon":0},{"id":"2484648603","title":"Alnylam Pharmaceuticals Says Nucresiran Performed Well in Phase 1 Transthyretin Amyloidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484648603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484648603?lang=en_us&edition=fundamental","pubTime":"2024-11-18 16:42","pubTimestamp":1731919364,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) said Sunday its phase 1 study of nucresiran as a potential treatment for transthyretin amyloidosis showed the drug's efficacy.Transthyretin amyloidosis is a condition ch","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY","BK4548","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2484865639","title":"Alnylam Pharmaceuticals announces interim Phase 1 data of nucresiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2484865639","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484865639?lang=en_us&edition=fundamental","pubTime":"2024-11-17 23:00","pubTimestamp":1731855604,"startTime":"0","endTime":"0","summary":"Alnylam (ALNY) Pharmaceuticals announced the presentation of new results from its Phase 1 study of nucresiran, a next-generation RNAi therapeutic i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-pharmaceuticals-announces-interim-phase-1-data-of-nucresiran?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-pharmaceuticals-announces-interim-phase-1-data-of-nucresiran?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","BK4139","BK4585","BK4588","BK4548"],"gpt_icon":0},{"id":"2484366286","title":"BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2484366286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484366286?lang=en_us&edition=fundamental","pubTime":"2024-11-17 22:40","pubTimestamp":1731854431,"startTime":"0","endTime":"0","summary":"BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single DoseNov 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4548","BK4139","ALNY","BK4585"],"gpt_icon":0},{"id":"2484368306","title":"Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2484368306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484368306?lang=en_us&edition=fundamental","pubTime":"2024-11-17 22:30","pubTimestamp":1731853825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4139","BK4548","ALNY"],"gpt_icon":0},{"id":"2484369846","title":"Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2484369846","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484369846?lang=en_us&edition=fundamental","pubTime":"2024-11-17 22:30","pubTimestamp":1731853800,"startTime":"0","endTime":"0","summary":"Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months. At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29. Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis. Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –。CAMBRIDGE, Mass., November 17, 2024----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran , a next-generation RNAi therapeutic in development for the treatment of transthyretin  amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago.In subjects receiving a single 300 mg dose of nucresiran, mean serum TTR reduction of 90.3% was observed at Day 15, 96.5% at Day 29, and 92","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lbdOYEv1xhxcIxqGMCFDuA--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ed49eae31affaa8c08885f7062a9a698","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lbdOYEv1xhxcIxqGMCFDuA--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ed49eae31affaa8c08885f7062a9a698"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-announces-interim-phase-1-143000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4218","LU1169589451.USD","BK4585","ALN","BK4023","BK4181","BK4139","PD","PK","BK4548","ALNY","LU1169590202.USD"],"gpt_icon":0},{"id":"2483053352","title":"Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2483053352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483053352?lang=en_us&edition=fundamental","pubTime":"2024-11-13 03:23","pubTimestamp":1731439415,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) shares were down more than 3% in recent Tuesday trading after Wolfe downgraded the stock to underperform from peer perform.Trading volume stood at about 505,000 shares against a daily average of roughly 817,000.Price: 268.98, Change: -10.84, Percent Change: -3.87","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"gpt_icon":0},{"id":"2482706989","title":"Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482706989?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:43","pubTimestamp":1731415423,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $178 to $400.(MT Newswires covers equity, commodity a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"gpt_icon":0},{"id":"2482796667","title":"Alnylam Pharmaceuticals Cut to Underperform From Peer Perform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2482796667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482796667?lang=en_us&edition=fundamental","pubTime":"2024-11-12 18:31","pubTimestamp":1731407460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2024 05:31 ET (10:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2482793617","title":"3 US Stocks Estimated To Be Trading At Discounts Up To 48.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482793617","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482793617?lang=en_us&edition=fundamental","pubTime":"2024-11-12 18:06","pubTimestamp":1731406003,"startTime":"0","endTime":"0","summary":"As U.S. stock markets reach record highs amid a post-election rally, investors are keenly observing the opportunities presented by undervalued stocks in this buoyant environment. Identifying such stocks often involves looking for companies with strong fundamentals that may not yet be fully reflected in their current market prices, offering potential value even as major indices continue to climb.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics based on ribonucleic acid interference, with a market cap of $35.78 billion.Operations: The company's revenue from its segment focused on the discovery, development, and commercialization of RNAi therapeutics amounts to $2.09 billion.Alnylam Pharmaceuticals, trading at US$279.82, is significantly below its estimated fair value of US$546.39","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0jRv83_m03r05H0SZtBfAw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/003f2dec604a7fb434c6feb185af4674","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0jRv83_m03r05H0SZtBfAw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/003f2dec604a7fb434c6feb185af4674"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-stocks-estimated-trading-100643148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DLR","BK4187","BK4548","ALNY","IE00B19Z9P08.USD","PINS","LU0348723411.USD","SNV","BK4551","BK4077","BK4534","IE00B894F039.SGD","LU2317271919.USD","BK4588","BK4566","BK4585","RKLB","BK4564","IE00B19Z9Z06.USD","BK4529","BK4222","IE00BZ9MQY76.HKD","BK4084","BK4508","BK4211"],"gpt_icon":1},{"id":"2482189597","title":"Alnylam cut to Underperform at Wolfe Research amid Amvuttra expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2482189597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482189597?lang=en_us&edition=fundamental","pubTime":"2024-11-12 10:05","pubTimestamp":1731377118,"startTime":"0","endTime":"0","summary":"Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-cut-to-underperform-at-wolfe-research-amid-amvuttra-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-cut-to-underperform-at-wolfe-research-amid-amvuttra-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","ALNY","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2482769274","title":"Alnylam downgraded to Underperform from Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2482769274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482769274?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:45","pubTimestamp":1731361515,"startTime":"0","endTime":"0","summary":"Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform, citing “unfriendly channel dynamics coupled with inability to rebate.” ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-downgraded-to-underperform-from-peer-perform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-downgraded-to-underperform-from-peer-perform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4139","BK4548","ALNY"],"gpt_icon":0},{"id":"2481486545","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481486545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481486545?lang=en_us&edition=fundamental","pubTime":"2024-11-05 14:21","pubTimestamp":1730787664,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Equillium (EQ – Research Report), Quest Diagnostic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-equillium-eq-quest-diagnostics-dgx-and-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-equillium-eq-quest-diagnostics-dgx-and-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4567","BK4548","BK4583","BK4137","BK4568","EQ","LU1854104046.USD","BK4139","DGX","HCSG","ALNY","BK4588","BK4196","BK4585","LU1854103824.USD"],"gpt_icon":0},{"id":"2480588662","title":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588662","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480588662?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., November 04, 2024----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:. UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT  at the Terranea Resort in Ranchos Palos Verdes, CA. Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:30 am GMT  in London","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oglEktbtXtmBqYkyKCIhfg--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d547f1b53b9d686c59eda5c4ed6fb0f7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oglEktbtXtmBqYkyKCIhfg--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d547f1b53b9d686c59eda5c4ed6fb0f7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-webcast-presentations-upcoming-november-130000402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","ALNY","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2480305728","title":"Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2480305728","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480305728?lang=en_us&edition=fundamental","pubTime":"2024-11-04 19:26","pubTimestamp":1730719560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 06:26 ET (11:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2480887911","title":"Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2480887911","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480887911?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:32","pubTimestamp":1730467920,"startTime":"0","endTime":"0","summary":"Alnylam recorded total revenues of $500.9 million in the quarter, which missed the Zacks Consensus Estimate of $529 million. In the year-ago quarter, total revenues were $750.5 million. The top line declined 33% year over year due to significantly lesser collaboration revenues earned in the reported quarter. Alnylam shares lost 5.3% on Thursday after the company reported its third-quarter results.Net revenues from collaborators were $57.4 million, down 87% from the year-ago quarter figure due to less revenues recognized under Alnylam’s ongoing collaborations with Roche RHHBY and Regeneron REGN.Year to date, shares of Alnylam have soared 39.3% against theindustry’s decline of 4.3%.Alnylam had earlier regained full global development and commercialization rights tomivelsiranin all indications, after Regeneron opted out of further co-development and co-commercialization of mivelsiran, in development for cerebral amyloid angiopathy and Alzheimer's disease. However, Regeneron will be eligib","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-q3-loss-line-estimates-133200994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALNY","NVS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0396},{"period":"1month","weight":-0.1695},{"period":"3month","weight":-0.1018},{"period":"6month","weight":0.6573},{"period":"1year","weight":0.5035},{"period":"ytd","weight":0.2794}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031314},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019432},{"month":5,"riseRate":0.6,"avgChangeRate":0.035453},{"month":6,"riseRate":0.619048,"avgChangeRate":0.064199},{"month":7,"riseRate":0.666667,"avgChangeRate":0.102356},{"month":8,"riseRate":0.571429,"avgChangeRate":0.032179},{"month":9,"riseRate":0.52381,"avgChangeRate":0.035035},{"month":10,"riseRate":0.380952,"avgChangeRate":-0.044018},{"month":11,"riseRate":0.761905,"avgChangeRate":0.08136},{"month":12,"riseRate":0.5,"avgChangeRate":0.016329}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction